Lercanidipine Actavis (Lercanidipine Hydrochloride)

Lercanidipine is a dihydropyridine calcium‑channel blocker used in the management of arterial hypertension. It works by relaxing vascular smooth muscle and lowering systemic vascular resistance.

• Essential hypertension: provides sustained reduction of systolic and diastolic blood pressure in patients with primary hypertension.
• Isolated systolic hypertension: effectively lowers elevated systolic pressure, particularly in older adults.
• Hypertension in the elderly: offers a once‑daily oral option with a favorable tolerability profile for senior patients.

• Lercanidipine selectively inhibits L‑type calcium channels in vascular smooth muscle, preventing calcium influx that is necessary for contraction. This inhibition leads to arterial vasodilation, decreased peripheral resistance, and consequently a reduction in systemic blood pressure without significant negative inotropic effects on the heart.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient. Patients should be aware of both common and serious possibilities.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: sensation of warmth and redness, typically resolves with continued therapy.
• Peripheral edema: swelling of ankles or lower legs, usually mild.
• Dizziness: may occur upon standing, especially after initial dosing.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Angioedema: swelling of face, lips, tongue, or throat, potentially life‑threatening.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Allergic reactions: rash, pruritus, or anaphylaxis in rare cases.

Before initiating therapy with Lercanidipine, several safety considerations should be reviewed.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Hepatic function: evaluate liver enzymes in patients with known liver disease.
• Aortic stenosis: use with caution in severe cases due to risk of reduced cardiac output.
• Elderly patients: start at low dose and monitor for dizziness or falls.
• Concomitant antihypertensives: adjust doses to prevent additive blood pressure lowering.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and risk of hypotension.
• Grapefruit juice: can elevate drug levels leading to enhanced vasodilatory effects.
• Co‑administration with other potent antihypertensives: may cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

• Diuretics: can amplify orthostatic hypotension.
• Beta‑blockers: monitor heart rate and blood pressure for additive effects.